Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Raises EPS, Revenue Guidance as Phadia Purchase Closes

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today raised its adjusted EPS and revenues guidance for full-year 2011 following the completion of its purchase of specialty diagnostics firm Phadia.

Thermo Fisher announced that its $3.5 billion purchase of the firm had closed and said that the acquisition is expected to contribute $.07 to full-year EPS, a $.01 increase from an original estimate of $.06, excluding restructuring, amortization of acquisition-related intangible assets, and other gains and costs.

As a result, it raised adjusted EPS guidance to a new range of between $4.15 and $4.25, which would represent a 20 percent to 23 percent increase over 2010 EPS. During its recent second-quarter earnings release, Thermo Fisher had given adjusted EPS guidance of between $4.08 and $4.18.

Phadia is also expected to contribute $190 million in revenues to Thermo Fisher for the year, and as a result the company raised its revenue guidance to a new range of $11.79 billion to $11.89 billion, which would represent around 12 percent growth over 2010.

Thermo Fisher had given guidance of between $11.60 billion to $11.70 billion last month.

Based in Uppsala, Sweden, Phadia has 1,500 employees worldwide and generated €367 ($529.5 million) in revenues in 2010. Phadia will become part of Thermo Fisher's Specialty Diagnostics business.

Following Thermo Fisher's announcement, Jon Wood of investment bank Jefferies raised his full-year 2011 EPS and revenue estimates for the company to $4.22 and $11.9 billion, respectively. He previously had estimated EPS of $4.15 on revenues of $11.7 billion.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.